Testosterone Formulations Adverse-Event Management Protocols

What Is the Testosterone Formulations Drug Class?

Testosterone formulations are exogenous androgen-replacement agents that restore serum testosterone to the eugonadal range (300 to 1,000 ng/dL per the American Urological Association) in men with confirmed hypogonadism. The class prototype is testosterone cypionate, an esterified injectable approved by the FDA in 1979. Other formulations include testosterone enanthate (injectable), testosterone undecanoate (injectable and oral), transdermal gels (AndroGel 1% and 1.62%, Testim, Vogelxo), transdermal patch (Androderm), nasal gel (Natesto), buccal system (Striant), subdermal pellets (Testopel), and subcutaneous injectable testosterone cypionate now widely used off-label in telehealth settings.

Each delivery system achieves eugonadal concentrations through a different pharmacokinetic curve, and that curve determines which adverse events predominate, when they appear, and how aggressively they must be managed.

Mechanism of Action and Pharmacokinetic Differences

Testosterone binds androgen receptors in skeletal muscle, bone, hypothalamus, prostate, and erythroid precursor cells. It is also aromatized peripherally to estradiol (E2), which governs bone density and libido to a significant degree. The esterified injectables undergo hydrolysis after injection, releasing free testosterone over days to weeks. Cypionate has a half-life of approximately 8 days; enanthate is approximately 4.5 days; undecanoate IM (Aveed) sustains levels for 10 to 14 weeks.

Transdermal gels deliver testosterone through stratum corneum absorption, producing relatively stable serum levels but introducing the possibility of secondary transfer to partners and children. Natesto (nasal) bypasses hepatic first-pass and produces pulsatile peaks that may preserve hypothalamic-pituitary-gonadal axis function in men who wish to preserve fertility.

Confirmed Diagnosis Requirement

Before initiating any formulation, two morning testosterone measurements below 300 ng/dL on separate days, combined with clinical symptoms, are required by Endocrine Society guidelines. The 2018 Endocrine Society Clinical Practice Guideline states: "We recommend confirming the diagnosis by repeating the measurement of serum total testosterone" [1]. Initiating therapy on a single low value or on symptoms alone increases the risk of treating men who do not need androgen replacement, exposing them to adverse events without benefit.

Erythrocytosis: The Most Common Serious Adverse Event

Erythrocytosis (hematocrit above 52% or hemoglobin above 17.5 g/dL) is the most frequently encountered serious adverse event across all testosterone routes. Injectable formulations produce it at a higher rate than transdermal routes. A 2017 meta-analysis by Fernández-Balsells et al. In the Annals of Internal Medicine found that injectable testosterone raised the odds of erythrocytosis significantly compared with baseline [2].

Monitoring Protocol

Obtain a complete blood count (CBC) with hematocrit at baseline, at 3 months after initiation, and every 6 to 12 months thereafter once stable. The Endocrine Society recommends withholding testosterone if hematocrit exceeds 54% [1]. At that threshold, the risk of thrombotic events rises measurably.

The practical decision tree:

• Hematocrit 52 to 54%: reduce dose or lengthen injection interval; recheck CBC in 6 weeks.
• Hematocrit above 54%: hold testosterone entirely; consider therapeutic phlebotomy (remove 1 unit whole blood); evaluate for secondary causes (sleep apnea, smoking, chronic hypoxia); restart at lower dose only after hematocrit returns below 50%.
• Persistent erythrocytosis despite dose reduction: switch formulation (transdermal typically produces lower peak testosterone and lower hematocrit response than IM cypionate).

Formulation-Specific Erythrocytosis Risk

Injectable testosterone cypionate 200 mg every 2 weeks produces supratherapeutic peaks of 1,200 to 1,500 ng/dL on day 2 to 3 post-injection, which drive erythropoiesis more aggressively than the plateau produced by daily transdermal application. Dividing the same weekly dose into twice-weekly or three-times-weekly subcutaneous injections flattens the peak and may reduce erythrocytosis incidence, though head-to-head randomized data for this specific outcome are limited. Testosterone undecanoate IM (Aveed) produces steadier levels and in the 4-year open-label extension showed a lower erythrocytosis rate than historical cypionate cohorts, though direct comparison is confounded by differences in patient populations [3].

Cardiovascular Adverse Events

TRAVERSE Trial Data

The cardiovascular safety of testosterone therapy was clarified substantially by the TRAVERSE trial (N=5,204 men aged 45 to 80 with hypogonadism and high cardiovascular risk), published in the New England Journal of Medicine in 2023. Testosterone undecanoate 1% gel produced non-inferiority to placebo for the primary MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) at a median of 22 months [4]. The MACE rate was 7.0% in the testosterone group vs. 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.78 to 1.17). Atrial fibrillation and acute kidney injury were numerically higher in the testosterone arm, though not statistically significant after multiplicity adjustment.

Prescriber Actions for Cardiovascular Risk

Screen all patients for pre-existing cardiovascular disease before initiation. For men with recent (within 6 months) myocardial infarction or stroke, the American Heart Association recommends deferring testosterone therapy pending cardiologist input. Monitor blood pressure at every follow-up; testosterone-related increases in red cell mass can secondarily raise systolic pressure. If systolic BP climbs more than 10 mmHg above baseline on a stable antihypertensive regimen, investigate erythrocytosis and fluid retention before attributing the rise to a separate cause.

Testosterone can also worsen heart failure through sodium and water retention. In men with NYHA Class III or IV heart failure, the risk-benefit ratio rarely favors initiation.

Skin and Local Adverse Events by Formulation

Transdermal Gels

Contact dermatitis occurs in roughly 5% of patients using testosterone gel. The most common culprit is the alcohol vehicle rather than testosterone itself. Switching brands (e.g., from AndroGel 1.62% to Testim) may resolve the reaction because Testim uses a different penetration enhancer. Mild erythema does not require discontinuation; moderate-to-severe reactions with vesiculation warrant a 2-week washout and skin assessment before re-challenge.

Secondary transfer remains a clinical and regulatory concern. The FDA required labeling changes in 2009 after reports of virilization in female partners and children exposed to gel residue on skin, clothing, and furniture. Management: apply gel to shoulders, upper arms, or abdomen; allow 5 minutes to dry; cover with clothing; wash hands immediately. Patients who cannot reliably prevent transfer (e.g., caregivers of young children) should consider non-transferable routes such as IM injection or nasal gel.

Transdermal Patches (Androderm)

Application-site reactions affect 30 to 44% of users of the Androderm patch, making it the formulation with the highest local-reaction rate. Rotating sites is mandatory. A mild topical corticosteroid (triamcinolone 0.1% cream) applied to the patch site 10 minutes before application reduces the incidence of moderate reactions without meaningfully altering testosterone absorption, according to product labeling guidance.

Subdermal Pellets (Testopel)

Pellet extrusion occurs in approximately 8% of insertions. Infection at the insertion site occurs in 1 to 3%. Fibrosis accumulates over repeated insertions. Prescribers should document cumulative insertion history and counsel patients that pellets cannot be removed quickly if an adverse event (e.g., new prostate cancer diagnosis) requires immediate testosterone cessation. This irreversibility window, typically 3 to 6 months until pellet resorption, is the primary risk-management consideration for this route.

Nasal Gel (Natesto)

Natesto 5.5 mg per actuation, applied three times daily, produces rhinorrhea in 6.5% of users and epistaxis in 1.8% based on key trial data [5]. Patients with chronic sinusitis, nasal polyps, or a recent nasal fracture are not good candidates. Assess nasal anatomy before prescribing.

Injectable Site Reactions

Testosterone cypionate IM injections in the gluteal or vastus lateralis muscle can produce oil embolism (rare but serious) if the needle enters a vein during gluteal injection without aspiration. Subcutaneous injection in the abdomen or thigh using a 27-gauge 0.5-inch needle eliminates the vascular embolism risk and is now preferred in most telehealth TRT protocols. Subcutaneous delivery with a 29-gauge insulin-style syringe in the abdomen produces comparable serum testosterone concentrations to IM in a pharmacokinetic comparison published in Postgraduate Medicine [6].

Prostate-Related Adverse Events

PSA Monitoring Schedule

A rise in PSA does not confirm prostate cancer, but testosterone therapy in men with occult prostate cancer can accelerate growth. The Endocrine Society 2018 guideline recommends PSA measurement at 3 to 6 months, then annually, with urology referral if:

• PSA rises more than 1.4 ng/mL above baseline within any 12-month period.
• PSA velocity exceeds 0.4 ng/mL per year over 2 years.
• A confirmed abnormality on digital rectal exam develops.

Before initiation, perform a digital rectal exam and obtain baseline PSA. Do not initiate testosterone in men with PSA above 4.0 ng/mL without prior urology evaluation.

Lower Urinary Tract Symptoms

Testosterone therapy does not cause benign prostatic hyperplasia but may worsen pre-existing LUTS in men with large glands. An International Prostate Symptom Score (IPSS) greater than 19 at baseline warrants urology input. If IPSS worsens by 4 or more points during therapy, evaluate prostate size and post-void residual before adjusting or continuing testosterone.

Gynecomastia and Estradiol Management

Testosterone aromatizes to estradiol. When serum estradiol rises above 40 pg/mL (some labs report this as 146 pmol/L), some men develop gynecomastia, nipple tenderness, or reduced libido attributable to estrogen-dominant symptoms. The response is formulation-independent, driven instead by aromatase activity (increased in obese men) and dose.

Management options:

• Reduce testosterone dose or injection frequency to lower the substrate for aromatization.
• Address obesity directly: each 10 kg of fat loss reduces aromatase burden measurably.
• Anastrozole 0.5 mg twice weekly is used off-label in TRT; it reduces estradiol effectively but carries risks of over-suppression (bone loss, joint pain, impaired libido) if estradiol falls below 20 pg/mL. Target estradiol of 20 to 30 pg/mL when using an aromatase inhibitor.

Routine co-prescription of anastrozole with every testosterone regimen is not supported by evidence. The Endocrine Society explicitly states aromatase inhibitors should be used only when symptomatic gynecomastia or very high estradiol accompanies therapy.

Fertility and Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone suppresses LH and FSH through negative feedback, causing intratesticular testosterone to drop and spermatogenesis to cease within 90 to 120 days in most men. This effect is dose-dependent and formulation-independent, though recovery may be faster after short-acting preparations than after pellets or undecanoate IM.

Management for Men Who May Want Future Fertility

For men who wish to preserve fertility, options include:

• Clomiphene citrate 25 to 50 mg every other day: raises endogenous LH and FSH, stimulates intratesticular testosterone without exogenous testosterone suppression. Off-label but well-documented in cohort data.
• Human chorionic gonadotropin (hCG) 500 IU subcutaneously three times per week: maintains intratesticular testosterone while exogenous testosterone is used, partially preserving testicular volume and sperm output.
• Natesto nasal gel: a 2019 study in the Journal of Urology (N=25) showed that three-times-daily Natesto maintained sperm concentration in most men by producing lower, pulsatile testosterone levels that did not fully suppress the axis [7].

Document fertility intent in every patient chart before prescribing. Men who discover during therapy that they want biological children often face a 6 to 18-month recovery window for spermatogenesis after discontinuation.

Sleep Apnea: Screening and Management

All testosterone formulations can worsen obstructive sleep apnea (OSA). The mechanism is a combination of upper airway muscle effects and direct respiratory drive changes. The Endocrine Society advises against initiating testosterone in men with severe untreated OSA.

Practical screening: ask about snoring, witnessed apneas, and daytime sleepiness at baseline. A STOP-BANG score of 5 or higher warrants polysomnography before testosterone initiation. If OSA is diagnosed, initiate CPAP first. Men already on CPAP can receive testosterone, but titration events should be rechecked 3 to 6 months after testosterone initiation.

Lipid and Metabolic Adverse Events

Testosterone therapy has variable effects on lipid panels. Injectable testosterone cypionate lowers HDL cholesterol by 10 to 14% in some cohorts, an effect not consistently seen with transdermal routes. Total cholesterol and LDL show smaller and less consistent changes. Obtain a fasting lipid panel at baseline and at 6 months. If HDL falls below 35 mg/dL, reassess the risk-benefit ratio, particularly in men with existing atherosclerotic cardiovascular disease.

Testosterone also lowers fasting insulin and improves insulin sensitivity in hypogonadal men with type 2 diabetes, which is a benefit rather than a risk, but it requires glucose monitoring adjustments: a T2D patient starting testosterone may need anti-diabetic medication dose reductions within 3 to 6 months.

Oral Testosterone (Jatenzo and Kyzatrex)

FDA-approved testosterone undecanoate oral capsules (Jatenzo, approved 2019; Kyzatrex, approved 2022) must be taken twice daily with food containing at least 20 grams of fat to ensure adequate lymphatic absorption via chylomicrons. Systemic bioavailability without fat is less than 10%.

Adverse events unique to the oral route:

• Hypertension: Jatenzo labeling carries a boxed warning for blood pressure increases. In key trials, mean systolic BP rose 3.5 to 5 mmHg from baseline. Check blood pressure at every visit and do not initiate in men with uncontrolled hypertension (systolic above 165 mmHg).
• Gastrointestinal discomfort: nausea and dyspepsia affect approximately 12% of patients.
• HDL lowering: oral route shows the most consistent HDL-lowering effect of all formulations due to partial hepatic first-pass exposure.

Stopping Testosterone: Discontinuation Protocol

When testosterone must be stopped abruptly (new prostate cancer, acute cardiovascular event, severe erythrocytosis, patient preference), several steps reduce withdrawal morbidity:

1. Counsel that symptoms of hypogonadism (fatigue, low libido, depressed mood) will return and may feel worse than pre-treatment baseline for 4 to 12 weeks while the axis recovers.
2. For short-acting formulations (cypionate, enanthate, transdermal gel), the axis begins recovering within 2 to 4 weeks of the last dose.
3. For Testopel pellets or Aveed IM, recovery may not begin for 3 to 6 months.
4. If rapid axis recovery is needed (e.g., desire for fertility), clomiphene 50 mg daily or hCG 1,500 IU three times weekly can accelerate LH and FSH recovery.
5. Recheck serum testosterone, LH, and FSH at 6 and 12 weeks after stopping.